- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
- -
-
Paragraph 0144; 0148
(2016/10/06)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula(I) or a pharmaceutically acceptable salt thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 80; 83
(2014/09/03)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 54; 57
(2014/07/08)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir 1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
- -
-
Page/Page column 39
(2013/05/21)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
- -
-
Page/Page column 58
(2013/07/05)
-
- INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
- -
-
Page/Page column 56; 59
(2013/03/26)
-
- Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
-
1-(4-aminophenyl)pyrazoles optionally substituted on the 3- and 5-positions of the pyrazole ring and on the amino group at the 4-position of the phenyl ring are disclosed and described, which pyrazoles inhibit IL-2 production in T-lymphocytes.
- -
-
-
- Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents
-
PCT No. PCT/SE97/00589 Sec. 371 Date Aug. 19, 1997 Sec. 102(e) Date Aug. 19, 1997 PCT Filed Apr. 9, 1997 PCT Pub. No. WO97/38977 PCT Pub. Date Oct. 23, 1997Compounds of formula I wherein R, R1, R2, and R3 and A are as defined herein, together with pharmaceutically acceptable salts, enantiomers or tautomers are useful as pharmaceuticals, particularly in the treatment of inflammatory disease.
- -
-
-
